Artelo Biosciences (ARTL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
7 Jan, 2026Executive summary
Annual Meeting of Stockholders is scheduled virtually for January 30, 2026, with registration required by January 29, 2026.
Stockholders will vote on three proposals: election of directors, advisory approval of executive compensation, and ratification of the independent auditor.
A revised proxy card and supplemental materials were distributed to include the new auditor ratification proposal.
Only stockholders of record as of December 10, 2025, are eligible to vote.
Voting can be done online, by phone, mail, or during the virtual meeting.
Voting matters and shareholder proposals
Proposal 1: Elect two Class II directors, Douglas Blayney, M.D., and Connie Matsui, to serve until the 2028 Annual Meeting.
Proposal 2: Advisory vote on the compensation of named executive officers as disclosed in the 2024 Summary Compensation Table.
Proposal 3: Ratification of MaloneBailey LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Board recommends a vote FOR all proposals.
Any other business properly brought before the meeting may also be considered.
Board of directors and corporate governance
Board has fixed December 10, 2025, as the record date for voting eligibility.
Board unanimously recommends the ratification of MaloneBailey LLP as auditor.
Proxy solicitation is conducted by the Board, with costs borne by the company.
Latest events from Artelo Biosciences
- Biopharma registers 9.8M shares for resale, targeting unmet needs but facing dilution risks.ARTL
Registration filing7 Apr 2026 - Equity line agreement enables up to $50M in funding but poses dilution and market risks.ARTL
Registration filing24 Mar 2026 - Biopharma seeks $10.9M via equity/warrants to fund clinical pipeline amid Nasdaq compliance risks.ARTL
Registration filing24 Mar 2026 - Lead programs show strong clinical progress in cancer anorexia, neuropathy, and anxiety.ARTL
Corporate presentation24 Mar 2026 - Biopharma seeks up to $10.8M via share/warrant offering to fund clinical pipeline, with dilution risk.ARTL
Registration filing23 Mar 2026 - Biopharma seeks $10.8M via stock and warrants to fund clinical pipeline, facing dilution and listing risks.ARTL
Registration filing20 Mar 2026 - Strong clinical advances offset by higher net loss and lower cash reserves in 2025.ARTL
Q4 202524 Feb 2026 - Net loss narrowed, cash runway extends into Q4 2025, and key clinical milestones are expected.ARTL
Q3 20245 Feb 2026 - All proposals passed, with directors re-elected and no shareholder questions submitted.ARTL
AGM 20262 Feb 2026 - Promising clinical pipeline in pain, cancer, and mental health, backed by strong IP and leadership.ARTL
Investor presentation30 Jan 2026